Borrego Écija, SergiPérez Millan, AgnèsAntonell Boixader, Anna, 1978-Fort Aznar, LauraKaya Tilki, E.León Halcon, A.Lladó Plarrumaní, AlbertMolina Porcel, LauraBalasa, MirceaJuncò Parella, J.Vitorica, J.Venero, J. L.Deierborg, T.Boza Serrano, A.Sánchez del Valle Díaz, Raquel2024-07-052024-07-052024-03-01https://hdl.handle.net/2445/214353INTRODUCTIONNeuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential.METHODSWe examined Gal-3 levels in brain, serum, and cerebrospinal fluid (CSF) samples of patients with FTD and controls. Multiple linear regressions between Gal-3 levels and other FTD markers were explored.RESULTSGal-3 levels were increased significantly in patients with FTD, mainly across brain tissue and CSF, compared to controls. Remarkably, Gal-3 levels were higher in cases with tau pathology than TAR-DNA Binding Protein 43 (TDP-43) pathology. Only MAPT mutation carriers displayed increased Gal-3 levels in CSF samples, which correlated with total tau and 14-3-3.DISCUSSIONOur findings underscore the potential of Gal-3 as a diagnostic marker for FTD, particularly in MAPT cases, and highlights the relation of Gal-3 with neuronal injury markers.12 p.application/pdfengcc by-nc-nd (c) Borrego Écija, Sergi et al, 2024http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/article2024-07-04info:eu-repo/semantics/openAccess938018438018380